Characterization of immunologically detectable T-cell sensitization, Immunohistochemical detection of pro-inflammatory cytokines, and clinical parameters of patients after allogeneic intraoral bone grafting procedures: a prospective randomized controlled clinical trial in humans
Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
Medientyp:
E-Artikel
Titel:
Characterization of immunologically detectable T-cell sensitization, Immunohistochemical detection of pro-inflammatory cytokines, and clinical parameters of patients after allogeneic intraoral bone grafting procedures: a prospective randomized controlled clinical trial in humans
Erschienen:
Springer Science and Business Media LLC, 2022
Erschienen in:BMC Oral Health
Sprache:
Englisch
DOI:
10.1186/s12903-022-02584-6
ISSN:
1472-6831
Entstehung:
Anmerkungen:
Beschreibung:
<jats:title>Abstract</jats:title><jats:sec>
<jats:title>Background</jats:title>
<jats:p>The null hypotheses were tested that intraoral bone augmentation using two different allogeneic materials has no impact on the patient’s blood levels of material-specific lymphocytes and on the immunohistochemical detection of pro-inflammatory cytokines IL-1α, IL1ß and TNF-α and T-cell markers CD4, CD8 in biopsies of the test groups.</jats:p>
</jats:sec><jats:sec>
<jats:title>Methods</jats:title>
<jats:p>In this prospective RCT, 60 systemically healthy participants were randomly assigned to two allogeneic test groups (1: Maxgraft®, freeze-dried, multiple donors, and 2: Puros®, solvent-dehydrated, single donor) and an autologous control group (10 patients). Plasma samples were collected pre-(T1) and postoperatively (2 weeks (T2) and 4 months (T3)). The Lymphocyte Transformation Test (LTT) was used for analyzing levels of transformed lymphocytes for type IV immune reactions by 3H-thymidine activity. Bone biopsies were harvested at T3 and immunohistochemically analyzed for IL-1α, IL1ß, TNF-α, CD4, CD8 and correlated with the immunological and clinical findings.</jats:p>
</jats:sec><jats:sec>
<jats:title>Results</jats:title>
<jats:p>A statistically significant difference between the tested materials was observed for LTT measurements at T3 (<jats:italic>p</jats:italic> = 0.033). Furthermore, three groups were identified: Group A (LTT negative T1-T3, <jats:italic>n</jats:italic> = 48), group B (LTT positive T1-T3, <jats:italic>n</jats:italic> = 7), group C (developing positive LTT at T2, <jats:italic>n</jats:italic> = 5). A highly significant elevation of IL-1α, IL1ß, TNF-α in patients of group C (<jats:italic>p</jats:italic> = 0.0001) and a significant elevation of CD4+ cells in patients of group B (<jats:italic>p</jats:italic> = 0.005) was shown.</jats:p>
</jats:sec><jats:sec>
<jats:title>Conclusion</jats:title>
<jats:p>Our data show that following allogeneic bone grafting, local and systemic immunological reactions can be detected in some patients. These findings were statistically significant for the timepoint T3 between the tested materials as well as for the groups B and C correlated with group A for both tested materials. Therefore, the null hypotheses were rejected. A preoperative compatibility test for allogeneic materials in order to improve patient safety and the predictability of these materials would be desirable.</jats:p>
</jats:sec><jats:sec>
<jats:title>Trial registration</jats:title>
<jats:p>Ethical commission of the Ärztekammer Hamburg, Germany (PV5211) as well as by the German Registry of Clinical Studies (DRKS00013010) on 30/07/2018 (<jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://apps.who.int/trialsearch/">http://apps.who.int/trialsearch/</jats:ext-link>).</jats:p>
</jats:sec>